Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample by A. Alkelai et al.
Association of the Type 2 Diabetes Mellitus Susceptibility
Gene, TCF7L2, with Schizophrenia in an Arab-Israeli
Family Sample
Anna Alkelai1., Lior Greenbaum1., Sara Lupoli2,3, Yoav Kohn1, Kyra Sarner-Kanyas1, Edna Ben-Asher4,
Doron Lancet4, Fabio Macciardi3,5, Bernard Lerer1*
1 Biological Psychiatry Laboratory, Dept. of Psychiatry, Hadassah - Hebrew University Medical Center, Jerusalem, Israel, 2 INSPE, Scientific Institute San Raffaele, Milan, Italy,
3Department of Sciences and Biomedical Technologies, University of Milan, Italy, 4Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel,
5Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, United States of America
Abstract
Many reports in different populations have demonstrated linkage of the 10q24–q26 region to schizophrenia, thus
encouraging further analysis of this locus for detection of specific schizophrenia genes. Our group previously reported
linkage of the 10q24–q26 region to schizophrenia in a unique, homogeneous sample of Arab-Israeli families with multiple
schizophrenia-affected individuals, under a dominant model of inheritance. To further explore this candidate region and
identify specific susceptibility variants within it, we performed re-analysis of the 10q24-26 genotype data, taken from our
previous genome-wide association study (GWAS) (Alkelai et al, 2011). We analyzed 2089 SNPs in an extended sample of 57
Arab Israeli families (189 genotyped individuals), under the dominant model of inheritance, which best fits this locus
according to previously performed MOD score analysis. We found significant association with schizophrenia of the TCF7L2
gene intronic SNP, rs12573128, (p = 7.0161026) and of the nearby intergenic SNP, rs1033772, (p = 6.5961026) which is
positioned between TCF7L2 and HABP2. TCF7L2 is one of the best confirmed susceptibility genes for type 2 diabetes (T2D)
among different ethnic groups, has a role in pancreatic beta cell function and may contribute to the comorbidity of
schizophrenia and T2D. These preliminary results independently support previous findings regarding a possible role of
TCF7L2 in susceptibility to schizophrenia, and strengthen the importance of integrating linkage analysis models of
inheritance while performing association analyses in regions of interest. Further validation studies in additional populations
are required.
Citation: Alkelai A, Greenbaum L, Lupoli S, Kohn Y, Sarner-Kanyas K, et al. (2012) Association of the Type 2 Diabetes Mellitus Susceptibility Gene, TCF7L2, with
Schizophrenia in an Arab-Israeli Family Sample. PLoS ONE 7(1): e29228. doi:10.1371/journal.pone.0029228
Editor: Abraham A. Palmer, University of Chicago, United States of America
Received April 10, 2011; Accepted November 22, 2011; Published January 11, 2012
Copyright:  2012 Alkelai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Israel Science Foundation (Israel Academy of Sciences, Grant 348/09) and by the 7th EU project POCEMON (FP7-ICT-
2007-216088). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lerer@cc.huji.ac.il
. These authors contributed equally to this work.
Introduction
Chromosome 10q is remarkably rich in linkage findings for
schizophrenia and bipolar disorder [1]. Seven reports in different
populations have demonstrated linkage of the 10q24–q26 region
to schizophrenia [2,3,4,5,6,7,8]. The studies, demonstrating
significant and suggestive schizophrenia linkage to 10q24-q26,
greatly encourage a search for specific schizophrenia susceptibility
genes in this region. Given the difference between studies in
localization of linkage peaks and the fact that peaks in this region
were not always the best detected ones in the cited studies, it is
reasonable that the region may harbor multiple schizophrenia
susceptibility genes with differential contributions to the phenotype
in terms of variant frequency, effect size and mode of inheritance
rather than a single schizophrenia susceptibility gene [9].
Lerer and collaborators (2003) [4] previously performed a
genome-wide linkage study of schizophrenia in a unique,
homogeneous sample of Arab-Israeli families with multiple
schizophrenia affected individuals and found suggestive linkage
to schizophrenia of the 10q24–q26 region, spanning from
D10S583 (94 Mb) to D10S217 (129 Mb). In a follow-up
publication (Alkelai et al, 2009) [1] we further explored this
region in exactly the same Arab sample, by genotyping additional
markers and applying additional analytic approaches. While
calculating the best-fitting penetrance for the 10q24–q26 locus
by maximization of parametric LOD scores over genetic model
parameters (MOD score analysis by varying penetrances and
disease allele frequency), we showed that the 10q24–q26 locus had
a dominant mode of inheritance in the studied Arab-Israeli
sample. We refined the linkage region to D10S222 (105.3 Mb) -
D10S587 (125.2 Mb) and also demonstrated genetic interaction of
this locus with an additional locus, 6q23.3, which was significantly
linked to schizophrenia [1]. Although the 10q24–q26 region
harbors a large number of protein coding genes (,130), many of
them expressed in the CNS, specific schizophrenia susceptibility
genes have not been identified in our sample.
Schizophrenia is a multifactorial, polygenic disorder. A large
number of genetic variants may be involved in its genetic
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background, some of them common, and others rare [10]. The
inheritance model of schizophrenia is unknown and the correct
model probably differs between risk markers. Our group recently
performed a genome-wide association study (GWAS) for schizo-
phrenia in an extended sample of Arab-Israeli families incorpo-
rating the families from our original report [11]. In the GWAS we
used the additive model of inheritance for the analysis of the data,
but none of the SNPs in the 10q24–q26 candidate region reached
genome-wide significance. The additive model is one of the most
common methods to analyze GWAS data when no previous
assumption about mode of inheritance is known. However, as
explained above, we showed (by MOD score analysis) that the
10q24–q26 locus had a dominant mode of inheritance in the
studied Arab-Israeli sample [1]. We raised the hypothesis, that in
this region the genetic contribution to schizophrenia should be
tested under a dominant model. Therefore, to be consistent with
our previous studies, we have chosen the dominant model for re-
analysis of the 10q24–q26 region in the current work. We
performed an association study of 2089 region positioned SNPs
with schizophrenia using the best-fitting dominant model of
inheritance, while appropriately correcting for multiple testing.
Methods
Ethics Statement
All participants gave written informed consent. The study was
approved by the Helsinki Committee (Internal Review Board) of
Hadassah – Hebrew University Medical Center, Jerusalem, Israel.
Sample
The studied sample was drawn from an ethnically homogenous
Arab population, recruited at the Taibe Regional Mental Health
Center in Israel, and included 58 nuclear families with 198
genotyped individuals of whom 95 are affected [4]. Additional
information about the studied sample may be found in ‘Detailed
description of the clinical sample and diagnostic methods’
(Information S1). The relatively small sample size in our study is
balanced by the unique nature of the population and decreased
genetic heterogeneity. Subjects with medical records of hospital-
izations and clinic care were questioned for psychiatric symptoms
in the family according to the Family History Research Diagnostic
Criteria (FH-RDC) [12] and were interviewed with the Schedule
for Affective Disorders and Schizophrenia- Lifetime Version
(SADS-L) [13] to establish psychiatric diagnosis. Research
Diagnostic Criteria (RDC) [14] and the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) [15] were
used for establishment of lifetime diagnoses using a best estimate
consensus procedure [16].
Genotyping
The Arab-Israeli sample was genotyped at the Platform of
Genomics and Bioinformatics, University of Milan on the
HumanCNV-370 BeadArrays (Illumina, San Diego, USA).
Normalized bead intensity data obtained for each sample were
analyzed with Illumina GenomeStudio 1.0.2 software [17,18].
PLINK version 1.06 software [19] was used to perform Quality
Control (QC) of the data. The procedure included: evaluation of
call rate; check of SNPs with (1) no calls, (2) genotyping rate less
than 0.9, (3) MAF less than 0.05; Hardy-Weinberg equilibrium
(HWE) testing (p,0.00001) in parents; and exclusion of
individuals with missing genotyping .10%. We also checked for
the assessment of genetic homogeneity according to the family,
sex-check and Mendelian transmission rate. SNPs with more than
10% and families with more than 5% Mendelian error rate were
discarded. The sex for each subject was estimated by the
GenomeStudio software. After QC procedure 57 nuclear families
with 189 genotyped individuals and 307472 autosomal SNPs
remained available for the association analysis [11].
Statistical analysis
For statistical analysis, we used PBAT Version 3.6 [20] which is
suitable for analysis of samples made up of different family-types.
PBAT statistics were calculated under the null hypothesis of
‘‘linkage-and-no-association’’ and using the sandwich option (sw)
for robust estimation of the variance, conditioning on traits and
parental genotypes. After restricting the number of informative
families to ten and QC procedure, 2089 SNPs located in the
10q24–q26 linkage region were available for analysis. As explained
in introduction, we used the dominant inheritance model in our
transmission disequilibrium test (TDT). Since this data was
previously analyzed by the additive model (as part of the GWAS
[11]), we calculated Bonferroni correction value for multiple
testing in relation to two analysis models per SNP (262089 tests).
We used PLINK [19] to estimate effect sizes for the implicated loci
in a subset of the sample that included only trios (since this option
is not available with PBAT).
To calculate power for dominant model, under a family-based
association framework, we used the approach suggested by Lange
and Laird (2002) [21] for FBAT, using the program PBAT. The
risk for schizophrenia according to the genotypes was modeled by
implementing a dominant model. We assumed that the marker
locus and the disease locus are different, and power was evaluated
for different marker allele frequencies ranging from 0.05 to 0.5.
Assuming a region-wide significance level, our analysis indicated
that the sample has a power of 30%2100% to detect significant
association of alleles with frequencies ranging from 0.05 to 0.5
under a transmission disequilibrium test (TDT) design and a
dominant model.
Results
We focused on the 10q24–q26 linkage region and re-analyzed
the available genotype data of 2089 SNPs positioned in this area
(taken from our previous GWAS (Alkelai et al, 2011) [11]) in order
to study association with schizophrenia under the dominant
model. We found two significant associations with schizophrenia
that survived region-wide correction for multiple testing (208962
tests , p-value,1.19761025), under the dominant model: TCF7L2
intronic SNP rs12573128 (p = 7.0161026) and the intergenic
SNP, rs1033772 (p = 6.5961026) (Figure 1, Table 1). rs1033772 is
located 318 kb from TCF7L2 and 65 kb from HABP2. The R-
square and D9 between these two SNPs are 0 and 0.14
respectively; therefore these two SNPs are not in linkage
disequilibrium (LD) (Figure 2). Information regarding nominal
association of all SNPs in this region (p,0.001) under the
dominant model is supplied in Table S1. The dominant and the
additive models are partially correlated to each other, and not
independent. Therefore, it is expected that at least partial overlap
between the top results of the two models will be observed.
Information regarding nominal association of all SNPs in this
region (p,0.001) under the additive model previously used in the
GWAS (Alkelai et al, 2011, [11]) is supplied in Table S2.
Overlapping positive results (p,161023) regarding the two
models, were found for a number of SNPs located within or near
different genes, including TCF7L2 SNP of interest, as well as for
additional SNPs in other genes (SORCS3, NRAP, GFRA1, TACC2,
and HMX3).
Schizophrenia and TCF7L2
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Figure 1. The 10q24-26 region. (a) Graphical representation of the linkage region including the genes within it. The map of the linkage region
was adapted from UCSC Genome Browser (http://genome.ucsc.edu/) (Mar. 2006 (NCBI36/hg18) assembly) (b) -log10(p-values) of all the SNPs
analyzed in the 10q24-26 region, employing the dominant model and according to the position of the SNPs on the chromosome.
doi:10.1371/journal.pone.0029228.g001
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Discussion
In the current study, we sought to identify novel schizophrenia
susceptibility variants within the 10q24–q26 region. The starting
point of this work was the prior Alkelai et al. (2009) linkage study
which used MOD score analysis to explore this region. This area
was reported by our [1,4] and other linkage studies [2,3,4,5,6,7,8]
to harbor schizophrenia susceptibility genes. Based on previous
linkage results supporting the relevance of a dominant model of
inheritance to this particular sample [1,4], we performed a region
specific association study of 2089 SNPs covering the area (for
which genotype data was available from our previous GWAS
Table 1. Significant results for association with schizophrenia.
SNP Bp Allele Freq Gen_rate Mend_err HW_parents OR p-value Gene
rs1033772 115235922 A 0.49 0.96 0 0.68 0.65 6.5961026 TCF7L2-HABP2
rs12573128 114720787 G 0.17 1 0 0.47 0.35 7.0161026 TCF7L2
P-values, allelic frequencies, and Hardy Weinberg equilibrium were obtained using PBAT. Genotyping rate, Mendelian errors, and OR were obtained using PLINK.
Abbreviations: HW=Hardy Weinberg equilibrium; allele =minor allele; freq = allele frequency; Gen_rate = genotyping rate, Mend_err =Mendelian errors.
doi:10.1371/journal.pone.0029228.t001
Figure 2. The TCF7L2 gene region. (a) The map of the genomic region adapted from UCSC Genome Browser (http://genome.ucsc.edu/) (Mar. 2006
(NCBI36/hg18) assembly) (b) Haploview representation of the LD structure between two TCF7L2 significant SNPs (rs12573128 and rs1033772). (c)
-log10(p-values) of all the SNPs analyzed between rs12573128 and rs1033772.
doi:10.1371/journal.pone.0029228.g002
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study (Alkelai et al, 2011) [11]) in a family based sample of Arab
Israeli origin, applying a dominant model of inheritance. We
found region-wide significant associations of two SNPs, one of
them located within TCF7L2 intron 4 (rs12573128,
p = 7.0161026) and the other an intergenic SNP (rs1033772,
p = 6.5961026), positioned 318 kb downstream to this gene and
65 kb from the HABP2 gene. Although both associations withstand
region-wide correction for multiple testing (208962 tests), the
findings should be regarded as preliminary and ‘‘hypothesis
generating’’ rather than definitive, and require further confirma-
tion in additional samples and populations.
Recently, several converging studies reported association of
different and independent genetic variants within or flanking
TCF7L2 with schizophrenia (data summarized in Table 2). Ben-
David and colleagues [22] showed association of the rs17746501
SNP (61 kb upstream to TCF7L2) with schizophrenia in a large
meta-analysis. An additional nearby intergenic SNP, rs11595716,
was associated with schizophrenia in an independent sample from
Germany, as reported by Need et al (2009) [23], although not in a
dominant model. Hansen and collaborators identified significant
association of a different TCF7L2 intronic variant (rs7903146) with
schizophrenia in a Danish sample, and this association was
replicated in a large multinational European sample of approx-
imately 4,000 schizophrenia patients and 17,500 controls [24].
Interestingly, this particular SNP was also genotyped and analyzed
in our Arab sample, but was not associated with schizophrenia.
Therefore, evidence is emerging to support involvement of several
independent SNPs within or flanking TCF7L2 in schizophrenia
susceptibility; some of them may be population specific.
The intergenic SNP rs1033772 is not in LD with the TCF7L2
gene or with rs12573128, and it is not clear if it exerts a biological
influence on this gene. Moreover, since this SNP is closer to
another gene, HABP2, we should not ignore the possibility that our
10q24–q26 region harbors more than one schizophrenia suscep-
tibility gene, acting independently: TCF7L2 and HABP2. More-
over, a third susceptibility gene for schizophrenia, FGFR2, was
found in this genomic area by O’Donovan et al (2009) [25].
HABP2 (hyaluronan binding protein 2), named also FSAP (serine
protease FVII activating protein) is an extracellular serine protease
that binds hyaluronic acid [26]. It is predominantly produced in
the liver, circulates in plasma and could cleave pro-urokinase,
coagulation factor VII, and platelet-derived growth factor [27].
Due to the current knowledge of biological role of this gene,
HABP2 seems to us as less attractive potential schizophrenia
susceptibility gene, compared to TCF7L2, although this may not
necessarily be true. Nevertheless since intergenic SNPs may
potentially influence expression of nearby genes (located 1 Mb
from the transcription start site) [28,29,30], we cannot exclude the
option that the intergenic SNP rs1033772 may affect TCF7L2
expression. This option should be tested experimentally.
Several limitations should be bear in mind when interpreting
our results. As in previous association studies in psychiatric
genetics published in recent years, it is possible that our findings
are false positive, particularly given the relatively small sample size.
Since the true mode of inheritance of schizophrenia is unknown,
and use of MOD score analysis could inflate the type I error, it is
possible that approximated model parameters do not reflect the
real mode of schizophrenia inheritance and the reported results
could be spurious. In addition, the correction for multiple testing
applied here is suited for a region-wide correction (required to
study the a priori research hypothesis) although genotype data
were taken from a much larger pool of 307472 autosomal SNPs
(originally analyzed under the additive model of inheritance). In
this regard the current analysis should be seen as complementary
to the original GWAS study, already published (Alkelai et al, 2011)
[11]. Last, we do not present here a replication trial in an
independent sample, which could have assist (if positive and
supports the association) in addressing this issue.
Nevertheless, these substantial limitations are balanced by
several factors, supporting the probability of a true positive. First,
our homogeneous family-based design is robust against false-
positive associations resulting from population stratification.
Second, we used strict correction for multiple testing (Bonferroni,
applied to the specific region of interest) in spite of the fact that the
existence of linkage disequilibrium (LD) in this area may render it
overly conservative. Even if multiple testing correction is taken for
all three main possible inheritance models used in the literature in
the context of schizophrenia (including the recessive model), the
results still pass the correction threshold. Third, the specific
inheritance model studied here (dominant) was chosen based on
evidence provided from the Arab Israeli families. The dominant
model of inheritance is acceptable and widely used in schizophre-
nia genetics research, both in candidate gene studies (eg. Kim et al,
2010; Xu et al, 2010; Okochi et al, 2009; Kim et al, 2008)
[31,32,33,34] and in GWASs (eg. Shifman et al, 2008) [35]. At the
molecular biology level, the implication of a TCF7L2 effect on
schizophrenia under the dominant model, is not clear and should
be further investigated. Fourth, our data are in line with the results
of other groups [22,23,24].
It is presumable that the identified intronic association signal is
in linkage disequilibrium with a schizophrenia causative variant,
which is specific to our particular Arab study sample. The family
based sample belongs to an ethnically homogeneous group that
has a high birthrate, an unusually high level of consanguinity and a
low rate of intermarriage with other population groups [36,37];
therefore a founder effect may exist in this population. On the
other hand, additional reported associations of TCF7L2 with
schizophrenia, described above (Table 2) probably represent more
generalized risk variants. Further studies including sequencing, in
this specific sample (whole TCF7L2 sequencing, searching for a
point mutations) and in independent samples, are required to
Table 2. Summary of positive association findings near the TCF7L2 gene (10q25.2-q25.3).
Study SNP Position on chromosome 10 Location P-value
Need et al. 2009 rs11595716 114633926 intergenic 261023
Ben-David et al. 2010 rs17746501 114639457 intergenic 761023
Hansen et al. 2011 rs7903146 114748339 intronic 561023
Current study rs12573128 114720787 intronic 761026
Current study rs1033772 115235922 intergenic 761026
doi:10.1371/journal.pone.0029228.t002
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properly address the issue of generalizability of the association to
other populations. In this regard, we are encouraged by our
previous success in verifying results following fine mapping in
another linkage region (6q23) in the same unique sample of Arab
Israelis. This led to identification of AHI1 as schizophrenia
susceptibility gene [37] which was further replicated in an
Icelandic case control sample [38] and recently in a large
European and Spanish/German samples [39,40]. AHI1 is located
in the linkage region which was previously shown to genetically
interact with the 10q24–q26 locus in our sample [1].
TCF7L2 is a confirmed type 2 diabetes (T2D) susceptibility gene
and is now a major focus of T2D genetic and molecular research.
Following the first report of Grant and colleagues [41] of
association of TCF7L2 gene variants with T2D, a large number
of studies in various populations have replicated the original
findings [42,43,44,45,46,47,48,49,50,51,52,53]. Several meta-
analyses further supported this robust finding [54,55]. Polymor-
phism within TCF7L2 was also associated with increased risk for
T2D among schizophrenia patients, in whom the disease is
relatively prevalent, as discussed below [56]. The functional role of
this gene in humans is under intense investigation [57,58].
Increased attention is now being given to a possible genetic basis
for comorbidity of T2D and schizophrenia [59]. The risk of T2D
is higher among schizophrenia patients than in the general
population of the same age group, mainly among young males
[60,61]. This is true even if schizophrenia patients are drug naı¨ve
[62]. First episode, drug naı¨ve schizophrenia patients had higher
fasting plasma glucose levels than controls [63] and a higher
incidence of T2D [64]. Nevertheless, it is difficult to determine if
diabetes and other glucose metabolism abnormalities stem from
schizophrenia itself or from treatment with antipsychotic medica-
tion [65]. Lin and Schuldiner [59] proposed that the co-
occurrence of the two disorders may be explained, at least
partially, by shared genetic risk variants. TCF7L2 may contain
independent variants for both disorders, or variants that exert
pleiotropic effect (the same variant causes the two different
pathological conditions).
Although much attention had been given to TCF7L2 function
in diabetes related organs such as pancreas, adipocytes and
intestine, its role in the brain is largely unknown. Lee and
collaborators reported high TCF7L2 expression in thalamic and
tectal adult mouse brain structures, with lower expression level in
the hypothalamus and additional areas [66]. Further studies
showed that TCF7L2 expression in the CNS is characterized by a
variety of splice variants. Nazwar et al [67] detected a
differentiation in TCF7L2 splice variant expression among post-
mitotic neurons, immature neural precursors and intestinal
epithelia in a murine model. At the primate level, TCF7L2 is
expressed in excitatory neurons in adult male rhesus monkeys
[68]. In humans, a unique splice variant was found in the brain,
islet and gut and therefore named the ‘‘neuroendocrine form’’.
This splice variant is highly expressed in the thalamus, occipital
lobe and hypothalamus [69]. Functionally, TCF7L2 is a
transcription factor involved in the Wnt/beta-catenin signaling
[70]. The Wnt signaling pathway plays role in the CNS
development [71,72], and has been also associated with schizo-
phrenia in a number of studies [73].
In conclusion, we performed re-analysis of the 10q24-q26
region association with schizophrenia. The results demonstrated
region-wide significant association of the T2D susceptibility gene,
TCF7L2 with the disease. This report strengthens the importance
of integrating several model of inheritance when analyzing
association studies in regions of interest. Validation studies in
other samples are warranted.
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